Literature DB >> 22083282

[Drug treatment of epilepsy].

D Schmidt1, G Krämer.   

Abstract

Modern medical treatment of epilepsy renders two out of three newly diagnosed epilepsy patients seizure-free. More than 20 drugs are currently available and even for epilepsy specialists it may not be easy to select the drug which is best suited for the individual patient. Current guidelines recommend drugs with proven efficacy and optimal tolerability that address the individual needs of the patient. Non-enzyme-inducing agents are preferred if possible, to protect the patient from loss of efficacy when taking other medications for life-threatening disorders. In one out of three patients, seizure freedom is currently not possible due to drug-resistance, which requires a prompt diagnostic and therapeutic reevaluation of the epilepsy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22083282     DOI: 10.1007/s00115-011-3342-3

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  16 in total

Review 1.  The pharmacological treatment of epilepsy in adults.

Authors:  Emilio Perucca; Torbjörn Tomson
Journal:  Lancet Neurol       Date:  2011-05       Impact factor: 44.182

Review 2.  Clinical practice. Initial management of epilepsy.

Authors:  Jacqueline A French; Timothy A Pedley
Journal:  N Engl J Med       Date:  2008-07-10       Impact factor: 91.245

Review 3.  Uncontrolled epilepsy following discontinuation of antiepileptic drugs in seizure-free patients: a review of current clinical experience.

Authors:  D Schmidt; W Löscher
Journal:  Acta Neurol Scand       Date:  2005-05       Impact factor: 3.209

Review 4.  Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis.

Authors:  Stefan Beyenburg; Knut Stavem; Dieter Schmidt
Journal:  Epilepsia       Date:  2009-09-10       Impact factor: 5.864

5.  Effectiveness of first antiepileptic drug.

Authors:  P Kwan; M J Brodie
Journal:  Epilepsia       Date:  2001-10       Impact factor: 5.864

6.  Risk of recurrent seizures after two unprovoked seizures.

Authors:  W A Hauser; S S Rich; J R Lee; J F Annegers; V E Anderson
Journal:  N Engl J Med       Date:  1998-02-12       Impact factor: 91.245

Review 7.  Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

Authors:  Jacqueline A French; Andres M Kanner; Jocelyn Bautista; Bassel Abou-Khalil; Thomas Browne; Cynthia L Harden; William H Theodore; Carl Bazil; John Stern; Steven C Schachter; Donna Bergen; Deborah Hirtz; Georgia D Montouris; Mark Nespeca; Barry Gidal; William J Marks; William R Turk; James H Fischer; Blaise Bourgeois; Andrew Wilner; R Edward Faught; Rajesh C Sachdeo; Ahmad Beydoun; Tracy A Glauser
Journal:  Epilepsia       Date:  2004-05       Impact factor: 5.864

8.  Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy.

Authors:  M J Brodie; E Perucca; P Ryvlin; E Ben-Menachem; H-J Meencke
Journal:  Neurology       Date:  2007-02-06       Impact factor: 9.910

Review 9.  Should enzyme-inducing antiepileptic drugs be considered first-line agents?

Authors:  Scott Mintzer; Richard T Mattson
Journal:  Epilepsia       Date:  2009-09       Impact factor: 5.864

10.  A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial.

Authors:  A G Marson; R Appleton; G A Baker; D W Chadwick; J Doughty; B Eaton; C Gamble; A Jacoby; P Shackley; D F Smith; C Tudur-Smith; A Vanoli; P R Williamson
Journal:  Health Technol Assess       Date:  2007-10       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.